Traws Pharma, Inc.
TRAW · XNASCIK 1130598fmd_0GDBSZM1YG020P5RGJA8ES8XJRManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2011 to Jun 30, 2026, 59 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 6 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 3 |
| Research and development | 20 | 19 | 17 | 16 | 17 | 7 | 11 | 11 | 13 | 12 |
| Total operating expenses | 29 | 27 | 25 | 24 | 25 | 17 | 20 | 21 | 143 | 21 |
| Operating income | (24) | (26) | (23) | (22) | (25) | (16) | (20) | (20) | (142) | (18) |
| Interest expense | – | – | – | – | – | – | – | – | – | – |
| Interest and investment income | – | – | – | – | – | – | 1 | 1 | 1 | 0 |
| Other non-operating income (expense) | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Income before taxes | (20) | (24) | (21) | (21) | (25) | (16) | (19) | (19) | (167) | 9 |
| Income tax expense | 0 | 0 | (0) | 0 | 0 | – | – | – | – | – |
| Net income from continuing operations | (20) | (24) | (20) | (22) | (25) | – | – | – | – | – |
| Net income | (20) | (24) | (21) | (22) | (25) | (16) | (19) | (19) | (167) | 9 |
| Net income to common shareholders | – | – | – | – | – | – | – | (19) | (55) | 7 |